Based in Cologne, Germany, Sividon Diagnostics is a management buyout from Siemens Healthcare Diagnostics in Cologne. The aim of Sividon team of experienced scientists and managers was and still is, the quality of companion diagnostics in oncology to improve their products sustainably. So in the future treatment decisions could in cancer - especially breast cancer - will be further improved by an individualized, evidence-based diagnosis. In this way Sividon is also supported by an established international network of renowned experts.
In addition to the many years of professional experience in molecular diagnostics, there are the extensive rights and to the year 2004 reaching back arrangements that characterize the team and Sividon.
Funding Rounds (1) - undisclosedUpdate
Current Team (5)Update
Board Members and Advisors (1)Update
|Jun 6, 2016||Med City News - Myriad touts studies at ASCO that back its transition toward panel testing for hereditary cancer|
|Jun 1, 2016||myriad.com - News Release|
|Jun 1, 2016||NASDAQ Global Newswire - Myriad Acquires Sividon Diagnostics|
|Jun 1, 2016||genengnews.com - Myriad Acquires Sividon Diagnostics for Up to $56M|
|Jun 1, 2016||Med City News - Morning Read: BioMarin pulls plug on $680M Duchenne drug, Valeant’s Pearson cashes in|
|Sep 3, 2011||FinSMEs - FinSMEs|
Nattermannallee 1 | S19
Kölln-reisiek, Schleswig-Holstein 50829